Drug Type Small molecule drug |
Synonyms Compound 30f |
Target |
Action antagonists, inhibitors |
Mechanism TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors), TrkC inhibitors(Neurotrophic tyrosine kinase receptor type 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC27H25F2N7 |
InChIKeyZJFBRVTUAWNZFO-UHFFFAOYSA-N |
CAS Registry2991504-43-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 01 Feb 2024 |